Published in Hum Brain Mapp on January 01, 2009
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology (2010) 1.22
Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch Gen Psychiatry (2010) 1.17
Identifying abnormal connectivity in patients using dynamic causal modeling of FMRI responses. Front Syst Neurosci (2010) 1.16
Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03
Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography. PLoS One (2012) 1.01
Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol (2012) 0.93
Autism spectrum traits predict the neural response to eye gaze in typical individuals. Neuroimage (2011) 0.91
Stochastic dynamic causal modeling of working memory connections in cocaine dependence. Hum Brain Mapp (2012) 0.86
Objective assessment of motor fatigue in Multiple Sclerosis using kinematic gait analysis: a pilot study. J Neuroeng Rehabil (2011) 0.84
Quantitative electroencephalography reveals different physiological profiles between benign and remitting-relapsing multiple sclerosis patients. BMC Neurol (2008) 0.81
Extra-visual functional and structural connection abnormalities in Leber's hereditary optic neuropathy. PLoS One (2011) 0.81
Altered patterns of cortical activation in ALS patients during attention and cognitive response inhibition tasks. J Neurol (2011) 0.80
Cluster analysis of behavioural and event-related potentials during a contingent negative variation paradigm in remitting-relapsing and benign forms of multiple sclerosis. BMC Neurol (2011) 0.79
The BDNF Val66Met polymorphism has opposite effects on memory circuits of multiple sclerosis patients and controls. PLoS One (2013) 0.75
Systematic imaging review: Multiple Sclerosis. Ann Indian Acad Neurol (2015) 0.75
Advanced magnetic resonance imaging techniques to better understand multiple sclerosis. Biophys Rev (2010) 0.75
How changes in brain activity and connectivity are associated with motor performance in people with MS. Neuroimage Clin (2017) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 5.31
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med (2010) 4.08
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (2002) 3.48
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. Am J Respir Crit Care Med (2010) 2.78
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler (2013) 2.20
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol (2009) 2.20
A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 2.13
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2012) 2.05
Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol (2005) 2.01
Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology (2012) 2.00
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain (2009) 1.89
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell (2008) 1.80
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol (2007) 1.73
White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain (2011) 1.73
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage (2010) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiol Aging (2011) 1.70
Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol (2002) 1.68
Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain (2008) 1.67
MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett (2011) 1.64
Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke (2008) 1.63
Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke (2006) 1.63
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.59
A modified damped Richardson-Lucy algorithm to reduce isotropic background effects in spherical deconvolution. Neuroimage (2009) 1.59
Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res (2010) 1.59
Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol Psychiatry (2013) 1.58
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin Exp Res (2009) 1.53
Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells (2007) 1.53
MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov Disord (2010) 1.52
Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol (2011) 1.52
Language networks in semantic dementia. Brain (2009) 1.50
Brain network connectivity assessed using graph theory in frontotemporal dementia. Neurology (2013) 1.50
Weighing brain activity with the balance: Angelo Mosso's original manuscripts come to light. Brain (2013) 1.50
Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A (2009) 1.49
Cortical lesions in multiple sclerosis. Nat Rev Neurol (2010) 1.47
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
Motor and language DTI Fiber Tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. Neuroimage (2007) 1.47
A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol (2010) 1.46
White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology (2010) 1.46
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology (2009) 1.45
A model-based deconvolution approach to solve fiber crossing in diffusion-weighted MR imaging. IEEE Trans Biomed Eng (2007) 1.44
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol (2009) 1.41
Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol (2011) 1.40
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Spontaneous intracerebral hemorrhage in Urbach-Wiethe disease. Neurology (2012) 1.39
Patent foramen ovale closure and brain ischaemic lesions. Heart (2013) 1.39
Migralepsy: a new case confirming the existence of this migraine complication and proposing therapy. Neurol Sci (2012) 1.39
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38